Skip to content

US · ACH · MEDICAL - DISTRIBUTION

Accendra Health, Inc. (ACH) intrinsic value and stock valuation

$0.02as of 2026-11-21 · Mkt cap 226.69M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Accendra Health, Inc. DCF and intrinsic value

InvestorsCraft values ACH with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ACH’s statements →

Accendra Health, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Distribution Glen Allen, VA 23060 accendrahealth.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$2.76B-20.1% 5y CAGRd
20112025
Net income
-$-1.1B
20112025
Free cash flow
-$-303.12M
20112025
Total equity
-$-460.98M
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$2.76B$10.7B$10.3B$9.96B$9.79B
Operating income$221.7M-$-207.77M$104.5M$142.9M$368.5M
Net income-$-1.1B-$-362.69M-$-41.3M$22.4M$221.6M
EPSd-$-14.31M-$-4.73M-$-545K$293.8K$2.94M
Operating cash flow-$-101.79M$161.5M$740.7M$325M$124.2M
Capital expenditure-$-201.32M-$-228.16M-$-207.89M-$-166.58M-$-49.69M
Free cash flow-$-303.12M-$-66.67M$532.8M$158.4M$74.5M
Total assets$2.45B$4.66B$5.09B$5.39B$3.54B
Total debt$2.23B$2.14B$2.41B$2.79B$1.15B
Net debt$1.95B$2.09B$2.16B$2.72B$1.1B
Total equity-$-460.98M$565.2M$924.2M$945.6M$938.5M
Cash and short-term investments$282M$49.4M$243M$69.5M$55.7M
Income statement
20252024202320222021
Revenue$2.76B$10.7B$10.3B$9.96B$9.79B
Cost of revenue$1.47B$8.48B$8.21B$8.13B$8.27B
Gross profit$1.29B$2.22B$2.13B$1.83B$1.51B
Research and development expenses$0.00$0.00$0.00$0.00$12.1M
Selling, general and administrative expenses$1.07B$1.91B$1.81B$1.55B$1.08B
Other expenses$0.00$517.1M$207.1M$128.6M$55.6M
Operating expenses$1.07B$2.43B$2.02B$1.68B$1.14B
Cost and expenses$2.54B$10.9B$10.2B$9.81B$9.42B
Interest income$0.00$0.00$0.00$0.00$0.00
Interest expense$107.2M$143.8M$157.9M$128.9M$48.1M
Depreciation and amortization$214.5M$264.8M$287.4M$228.7M$90.6M
Ebitda$219.8M$51.2M$390.6M$368.5M$415.5M
Operating income$221.7M-$-207.77M$104.5M$142.9M$368.5M
Total other income/expenses, net-$-323.69M-$-149.59M-$-159.23M-$-132.02M-$-91.72M
Income before tax-$-101.95M-$-357.36M-$-54.73M$10.9M$276.8M
Income tax expense$730K$5.33M-$-13.43M-$-11.5M$55.2M
Net income-$-1.1B-$-362.69M-$-41.3M$22.4M$221.6M
Weighted average shares outstanding$76.9M$76.7M$75.8M$74.5M$72.7M
Weighted average diluted shares outstanding$76.9M$76.7M$75.8M$76.2M$75.5M
Balance sheet
20252024202320222021
Cash and short-term investments$282M$49.4M$243M$69.5M$55.7M
Net receivables$95.9M$690.2M$598.3M$763.5M$681.6M
Inventory$74.4M$1.13B$1.11B$1.33B$1.5B
Total current assets$547.9M$2.02B$2.1B$2.3B$2.32B
Property, plant and equipment, net$365.3M$865M$840.5M$858.9M$511.2M
Goodwill and intangible assets$1.36B$1.63B$2B$2.12B$633.9M
Long-term investments$1.34M$6.11M$8.45M$15.5M$16.3M
Total non-current assets$1.9B$2.63B$2.99B$3.09B$1.21B
Total assets$2.45B$4.66B$5.09B$5.39B$3.54B
Accounts payable$363.6M$1.25B$1.17B$1.15B$1B
Short-term debt$293.3M$45.2M$292.6M$94.7M$43.9M
Deferred revenue$0.00$0.00$116.4M$0.00$0.00
Total current liabilities$947.1M$1.87B$1.89B$1.57B$1.34B
Long-term debt$1.94B$2.1B$2.11B$2.7B$1.11B
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.97B$2.22B$2.28B$2.87B$1.25B
Capital lease obligations$70.3M$300.7M$320.5M$306.7M$173.6M
Total liabilities$2.91B$4.09B$4.17B$4.44B$2.6B
Common stock$152.8M$154.4M$153.1M$152.6M$150.9M
Retained earnings-$-1.08B$6.02M$368.7M$410M$387.6M
Accumulated other comprehensive income (loss)-$-890K-$-49.34M-$-31.82M-$-35.85M-$-40.59M
Total equity-$-460.98M$565.2M$924.2M$945.6M$938.5M
Total investments$1.34M$6.11M$8.45M$15.5M$16.3M
Total debt$2.23B$2.14B$2.41B$2.79B$1.15B
Net debt$1.95B$2.09B$2.16B$2.72B$1.1B
Cash flow statement
20252024202320222021
Net income-$-102.68M-$-362.69M-$-41.3M$22.4M$221.6M
Depreciation and amortization$214.5M$264.8M$287.4M$228.7M$90.6M
Stock-based compensation$12.9M$26.8M$23.2M$21M$25M
Change in working capital$65.2M-$-25.44M$522.3M$89.8M-$-261.4M
Accounts receivable$122.4M-$-94.55M$166.6M$1.1M-$-2.2M
Inventory-$-6.85M-$-26.23M$224.3M$166.6M-$-263.44M
Accounts payable$6.48M$65.2M$31M$13.7M$3.55M
Net cash provided by operating activities-$-101.79M$161.5M$740.7M$325M$124.2M
Investments in property, plant and equipment-$-190.96M-$-210.87M-$-190.87M-$-166.58M-$-49.69M
Acquisitions, net$324.3M$0.00$0.00-$-1.68B-$-43.37M
Net cash used for investing activities$144.4M-$-116.53M-$-137.25M-$-1.8B-$-53.63M
Common stock issued$0.00$0.00$0.00$0.00$0.00
Common stock repurchased-$-10.18M$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00-$-730K
Net cash used for financing activities$188.1M-$-267.6M-$-417.33M$1.5B-$-129.48M
Net change in cash$232.6M-$-223.54M$186.7M$14.2M-$-62.47M
Cash at end of period$282M$49.4M$272.9M$86.2M$72M
Operating cash flow-$-101.79M$161.5M$740.7M$325M$124.2M
Capital expenditure-$-201.32M-$-228.16M-$-207.89M-$-166.58M-$-49.69M
Free cash flow-$-303.12M-$-66.67M$532.8M$158.4M$74.5M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Accendra Health, Inc.

        Accendra Health, Inc., along with its subsidiaries, operates globally as a comprehensive provider of healthcare solutions. The organization is structured into two primary operational divisions: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment offers a wide array of goods and support services to both healthcare providers and manufacturers. Its extensive catalog includes medical and surgical supplies, featuring both established brands and its own proprietary merchandise. This segment also delivers crucial services to healthcare providers, such as supplier relationship management, advanced analytics, inventory optimization, and clinical supply oversight. Furthermore, it provides outsourced logistics and marketing assistance programs to its vendor partners. The Patient Direct segment is dedicated to delivering products and services for at-home patient care. Its offerings encompass critical therapeutic fields such as diabetes management, home-based respiratory support, and obstructive sleep apnea therapy. This division also supplies various other types of home medical equipment, as well as specialized patient care products for conditions like ostomy, wound management, urological needs, and incontinence. Accendra Health serves a diverse client base directly, including large multi-facility healthcare systems, independent hospitals, surgical facilities, and physicians' practices. Additionally, it reaches customers indirectly through third-party distribution channels. The enterprise was formerly known as Owens & Minor, Inc., adopting the name Accendra Health, Inc. in December 2025. Founded in 1882, its headquarters are located in Glen Allen, Virginia.

        CEO
        Edward A. Pesicka
        Employees
        6.5K
        Beta
        1.58

        Explore

        Frequently asked questions

        What is the intrinsic value of Accendra Health, Inc. (ACH)?

        InvestorsCraft does not currently publish an intrinsic value for ACH. How the IC value is calculated.

        Is ACH undervalued?

        InvestorsCraft does not publish an undervaluation signal for ACH at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.